Nymox Pharmaceutical Corp was incorporated under the Canada Business Corporations Act in May 1995. The Company is a biopharmaceutical corporation engaged in research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease. It has three proprietary products on the market, and a significant R&D pipeline of products in development for the treatment of such conditions and diseases as BPH, prostate cancer, Alzheimer's disease or AD, E. coli O157; H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company also has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's products include: NicAlert, TobacAlert and AlzheimAlert. The Company has developed and markets NicAlert and TobacAlert, test strips for determining whether a person is using tobacco products or has been recently exposed to second-hand smoke. It has also developed AlzheimAlert, a proprietary urine assay that can aid physicians in the diagnosis of Alzheimer's disease. The Company is also developing NX-1207, treatments for BPH and prostate and liver cancer. It is also developing NXC-4720, novel antibacterial agents for the treatment of E. coli O157 bacterial contamination in meat and other food and drink products. Its AlzheimAlert test is certified with a CE Mark, making the device eligible for sale in the European Union. The Company's competitors include: Eli Lilly and Company, GE Healthcare, Athena Diagnostics, Inc., Fujirebio Europe NV, Amorfix Life Sciences Ltd, LabCorp, Quest Diagnostics, OraSure Technologies Inc., Abraxis LLC, Roche Diagnostics, Abbott and Diagnostic Products Corporation.